Member Info for AnthonyW

Mr Shrewd. Dex is cheap. Its not used until patients are on ventilation. The others are also used at late stage but are no way described as cheap

It's made in the EU and now a site in America. Will only be able to blacklist stuff that comes into the UK

39 is fine for a phase 1 its done its initial job. If they are happy with the dose they might then move onto a phase 2/3 (depending on if they are confident with the dose used)

£2 based on what? If there's a successful phase 3 it's going to be alot, alot higher.
Take your profit by all means.

No not at all. Mabs are very specific. Sng01 is a broad spectrum that can be used for any further mutations and stock piled by government. Plus it can be given at home via a nebuliser rather than in hospital by injection...

So lateral flows can have pics uploaded via mobile apps at testing centres?

You can't pick up antibody in saliva or sputum. Blood is the only place that pick up a detectable level.

Thanks for the info. It's going to be a crowded space.

Can you provide a link to ncyt bead development? I hear they are aiming to make lateral flow but not beads.

I imagine a purchase of gdr would be by a large partner if there are huge contracts awarded

What time do we expect the AIM awards today? Synairgen have been nominated.

Can't speak of the PRIME process. Normally with a positive CHMP by EMA it goes to the EU for adoption or not. It's usually within a month of this.

Surely you mean to 'tell the truth'

Governments could pay in advance for their orders which should help with cash flow

Do we know what % of sng is owned by our cousins across the sea?

The cynic in me thinks noteworthy news for sng might be related to the elections going on over there. A big deal was made of plasma therapy which is frankly underwhelming.
I'm guessing if it's good he will use it to a white Knight AZ vaccines are taking too long for him.

Reckon it could be sng001?

The German speaker (didn't place his name, perhaps it was Axel ? ) during their investor call seemed very excited by the potential in influenza.

To me, it's encouraging and its means they are happy that the internal signal they have seen means they can make the trial bigger and commit resources to it. Scientific language is deliberately nuanced.
For those wanting an idea of the aims of the different phases of trial:
Phase 1 = Mainly to establish what is the right dose along with safety. Generally very small number of patients. Cannot register with FDA etc with Phase 1
Phase 2=Using the dose established from Phase 1 in a larger number of patients. Main aim is to look at safety with some look at signal. In a rare disease (very small numbers (IBS is not one) ) they can register if there is an unmet need (no other treatment available) they can register with FDA etc if there is a treatment response and has acceptable safety.
Phase 3= This is the gold standard for registering a treatment. Large numbers of patients randomised against what the standard of care is.

Thanks for this!

I don't know if this will help some but I have a definition for the term futility as applied to a trial setting. The term 'futility' is used to refer to the inability of a clinical trial to achieve its objectives. In particular, stopping a clinical trial when the interim results suggest that it is unlikely to achieve statistical significance can save resources that could be used on more promising research. So being not futile is a good thing. It means it can carry on to a bigger trial...

Apologies for the naive question regarding dual listing. If 4D list on nasdaq will there be any upside for us AIM share holders?